Total Payments
$50,588
2024 Payments
$13,532
Companies
12
Transactions
60
Medicare Patients
10,588
Medicare Billing
$1.2M
Payment Breakdown by Category
Consulting$27,367 (54.1%)
Other$20,400 (40.3%)
Travel$1,476 (2.9%)
Food & Beverage$1,344 (2.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $27,367 | 12 | 54.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $12,400 | 6 | 24.5% |
| Honoraria | $8,000 | 4 | 15.8% |
| Travel and Lodging | $1,476 | 18 | 2.9% |
| Food and Beverage | $1,344 | 20 | 2.7% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amarin Pharma Inc. | $12,996 | 18 | $0 (2024) |
| Regeneron Pharmaceuticals, Inc. | $8,835 | 14 | $0 (2018) |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $8,000 | 4 | $0 (2022) |
| AstraZeneca Pharmaceuticals LP | $6,432 | 9 | $0 (2018) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $3,749 | 3 | $0 (2024) |
| Lilly USA, LLC | $3,500 | 2 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $2,873 | 2 | $0 (2017) |
| Regeneron Healthcare Solutions, Inc. | $2,500 | 1 | $0 (2021) |
| Allergan Inc. | $1,185 | 3 | $0 (2017) |
| ZOLL Medical Corporation | $432.15 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $13,532 | 12 | Amarin Pharma Inc. ($6,492) |
| 2023 | $6,936 | 10 | Amarin Pharma Inc. ($6,504) |
| 2022 | $4,000 | 2 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) ($4,000) |
| 2021 | $6,600 | 4 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) ($4,000) |
| 2020 | $109.25 | 1 | Boehringer Ingelheim Pharmaceuticals, Inc. ($109.25) |
| 2019 | $24.97 | 1 | Novartis Pharmaceuticals Corporation ($24.97) |
| 2018 | $15,317 | 24 | Regeneron Pharmaceuticals, Inc. ($8,835) |
| 2017 | $4,069 | 6 | SANOFI-AVENTIS U.S. LLC ($2,873) |
All Payment Transactions
60 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/02/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $3,540.00 | General |
| 06/06/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Consulting Fee | Cash or cash equivalent | $1,400.00 | General |
| Category: Diabetes | ||||||
| 04/19/2024 | Amarin Pharma Inc. | Vascepa (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,600.00 | General |
| Category: cardiovascular | ||||||
| 04/11/2024 | Amarin Pharma Inc. | Vascepa (Drug) | Food and Beverage | In-kind items and services | $109.70 | General |
| Category: cardiovascular | ||||||
| 04/11/2024 | Amarin Pharma Inc. | Vascepa (Drug) | Travel and Lodging | Cash or cash equivalent | $20.64 | General |
| Category: cardiovascular | ||||||
| 04/11/2024 | Amarin Pharma Inc. | Vascepa (Drug) | Travel and Lodging | Cash or cash equivalent | $10.00 | General |
| Category: cardiovascular | ||||||
| 04/09/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Consulting Fee | Cash or cash equivalent | $2,100.00 | General |
| Category: Diabetes | ||||||
| 02/21/2024 | Amarin Pharma Inc. | Vascepa (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,600.00 | General |
| Category: cardiovascular | ||||||
| 02/01/2024 | Amarin Pharma Inc. | Vascepa (Drug) | Food and Beverage | In-kind items and services | $124.99 | General |
| Category: cardiovascular | ||||||
| 02/01/2024 | Amarin Pharma Inc. | Vascepa (Drug) | Travel and Lodging | Cash or cash equivalent | $17.15 | General |
| Category: cardiovascular | ||||||
| 02/01/2024 | Amarin Pharma Inc. | Vascepa (Drug) | Travel and Lodging | Cash or cash equivalent | $10.00 | General |
| Category: cardiovascular | ||||||
| 01/26/2024 | Amarin Pharma Inc. | Vascepa (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,000.00 | General |
| Category: cardiovascular | ||||||
| 12/12/2023 | Amarin Pharma Inc. | Vascepa (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,600.00 | General |
| Category: Cardiovascular | ||||||
| 12/12/2023 | Amarin Pharma Inc. | Vascepa (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,600.00 | General |
| Category: Cardiovascular | ||||||
| 11/30/2023 | Amarin Pharma Inc. | Vascepa (Drug) | Food and Beverage | In-kind items and services | $124.99 | General |
| Category: Cardiovascular | ||||||
| 11/30/2023 | Amarin Pharma Inc. | Vascepa (Drug) | Travel and Lodging | Cash or cash equivalent | $16.77 | General |
| Category: Cardiovascular | ||||||
| 11/30/2023 | Amarin Pharma Inc. | Vascepa (Drug) | Travel and Lodging | Cash or cash equivalent | $10.00 | General |
| Category: Cardiovascular | ||||||
| 11/07/2023 | Amarin Pharma Inc. | Vascepa (Drug) | Food and Beverage | In-kind items and services | $124.99 | General |
| Category: Cardiovascular | ||||||
| 11/07/2023 | Amarin Pharma Inc. | Vascepa (Drug) | Travel and Lodging | Cash or cash equivalent | $16.77 | General |
| Category: Cardiovascular | ||||||
| 11/07/2023 | Amarin Pharma Inc. | Vascepa (Drug) | Travel and Lodging | Cash or cash equivalent | $10.00 | General |
| Category: Cardiovascular | ||||||
| 09/22/2023 | Amarin Pharma Inc. | Vascepa (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,000.00 | General |
| Category: Cardiovascular | ||||||
| 01/05/2023 | ZOLL Medical Corporation | — | Consulting Fee | Cash or cash equivalent | $432.15 | General |
| Category: DEFIBRILLATOR | ||||||
| 12/07/2022 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | LifeVest (Device) | Honoraria | Cash or cash equivalent | $2,000.00 | General |
| Category: Electromedical and Electrotherapeutic Apparatus | ||||||
| 11/16/2022 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | LifeVest (Device) | Honoraria | Cash or cash equivalent | $2,000.00 | General |
| Category: Electromedical and Electrotherapeutic Apparatus | ||||||
| 12/22/2021 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | LifeVest (Device) | Honoraria | Cash or cash equivalent | $2,000.00 | General |
| Category: Electromedical and Electrotherapeutic Apparatus | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 21 | 3,479 | 12,585 | $2.7M | $435,545 |
| 2022 | 14 | 2,441 | 3,461 | $1.5M | $233,040 |
| 2021 | 14 | 2,551 | 3,762 | $1.3M | $274,079 |
| 2020 | 14 | 2,117 | 3,322 | $1.2M | $221,839 |
Total Patients
10,588
Total Services
23,130
Medicare Billing
$1.2M
Procedure Codes
67
All Medicare Procedures & Services
67 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 519 | 1,149 | $1.1M | $178,558 | 15.9% |
| J1306 | Injection, inclisiran, 1 mg | Office | 2023 | 16 | 7,384 | $265,824 | $69,577 | 26.2% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 288 | 298 | $446,702 | $52,903 | 11.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 157 | 285 | $196,365 | $32,440 | 16.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 131 | 131 | $158,772 | $24,779 | 15.6% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 95 | 171 | $78,660 | $18,721 | 23.8% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2023 | 200 | 200 | $73,152 | $11,659 | 15.9% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2023 | 1,029 | 1,508 | $66,352 | $10,889 | 16.4% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 536 | 836 | $116,204 | $10,759 | 9.3% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 49 | 51 | $44,829 | $8,136 | 18.1% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Facility | 2023 | 80 | 80 | $32,155 | $5,349 | 16.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 29 | 34 | $16,796 | $2,823 | 16.8% |
| 93016 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | Facility | 2023 | 100 | 101 | $12,120 | $1,817 | 15.0% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 16 | 24 | $7,728 | $1,609 | 20.8% |
| 93797 | Outpatient heart rehabilitation, qualified health care professional services | Office | 2023 | 15 | 95 | $9,500 | $1,499 | 15.8% |
| 93018 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | Facility | 2023 | 100 | 101 | $7,878 | $1,210 | 15.4% |
| 93224 | Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | Office | 2023 | 17 | 17 | $14,909 | $1,099 | 7.4% |
| 93244 | Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | Office | 2023 | 19 | 20 | $2,400 | $417.80 | 17.4% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 17 | 31 | $3,565 | $397.73 | 11.2% |
| 93356 | Heart muscle strain imaging | Facility | 2023 | 33 | 33 | $7,293 | $350.46 | 4.8% |
| 93308 | Ultrasound of heart, follow-up | Facility | 2023 | 14 | 14 | $1,963 | $286.91 | 14.6% |
| 93242 | Heart rhythm recording continous external ekg over more than 48 hours up to 7 days | Office | 2023 | 19 | 22 | $1,826 | $263.78 | 14.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 396 | 753 | $737,187 | $120,212 | 16.3% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2022 | 114 | 121 | $181,379 | $22,470 | 12.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 128 | 183 | $126,087 | $20,907 | 16.6% |
About Dr. Benjamin Hirsh, M.D
Dr. Benjamin Hirsh, M.D is a Cardiovascular Disease healthcare provider based in Manhasset, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/13/2010. The National Provider Identifier (NPI) number assigned to this provider is 1548586712.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Benjamin Hirsh, M.D has received a total of $50,588 in payments from pharmaceutical and medical device companies, with $13,532 received in 2024. These payments were reported across 60 transactions from 12 companies. The most common payment nature is "Consulting Fee" ($27,367).
As a Medicare-enrolled provider, Hirsh has provided services to 10,588 Medicare beneficiaries, totaling 23,130 services with total Medicare billing of $1.2M. Data is available for 4 years (2020–2023), covering 67 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location Manhasset, NY
- Active Since 04/13/2010
- Last Updated 07/21/2022
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1548586712
Products in Payments
- Vascepa (Drug) $12,996
- PRALUENT ALIROCUMAB INJECTION (Biological) $8,835
- LifeVest (Device) $8,000
- BRILINTA (Drug) $6,432
- MOUNJARO (Drug) $3,500
- NO PRODUCT DISCUSSED (Drug) $2,873
- EVKEEZA (Biological) $2,500
- JARDIANCE (Drug) $209.07
- Repatha (Biological) $11.57
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Manhasset
Bruce Rutkin, Md, MD
Cardiovascular Disease — Payments: $328,717
Cardiovascular Disease $328,717
Mitchell Weinberg, Md, MD
Cardiovascular Disease — Payments: $163,984
Cardiovascular Disease $163,984
Dr. Perwaiz Meraj, M.d, M.D
Cardiovascular Disease — Payments: $121,905
Cardiovascular Disease $121,905
Dr. Andrea Mignatti, M.d, M.D
Cardiovascular Disease — Payments: $24,976
Cardiovascular Disease $24,976
Michael Mannino, M.d, M.D
Cardiovascular Disease — Payments: $20,568
Cardiovascular Disease $20,568
Stuart Beldner, Md, MD
Cardiovascular Disease — Payments: $19,150
Cardiovascular Disease $19,150